Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600–Mutant Tumors

BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF inhibition in BRAF V600–mutated colorectal cancer has prevented its tissue-agnostic drug development. We reviewed the AACR G...

Descripción completa

Detalles Bibliográficos
Autores principales: Adashek, Jacob J., Menta, Arjun K., Reddy, Neha K., Desai, Aakash P., Roszik, Jason, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355618/
https://www.ncbi.nlm.nih.gov/pubmed/35413124
http://dx.doi.org/10.1158/1535-7163.MCT-21-0950

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355618/
https://www.ncbi.nlm.nih.gov/pubmed/35413124
http://dx.doi.org/10.1158/1535-7163.MCT-21-0950

Ejemplares similares